The Department of War is required by law to maintain an integrated Military Health System pharmacy benefits program, including pharmaceutical purchases, with P&T Committee recommendations on Uniform Formulary placement and cost-sharing classifications based on relative clinical and cost effectiveness. An RFQ has been issued for pharmaceutical agents in drug classes identified for Uniform Formulary placement, and DHA may award Uniform Formulary Blanket Purchase Agreements and Uniform Formulary Additional Discount Program Agreements based on the UF decision. The February 2027 P&T Committee meeting will review newly approved drugs: Atebrioz (skeletal muscle relaxants and combinations), Emcitate (thyroid/antithyroid agents), Hibsago (hepatitis B agents), Juvmo (Parkinson’s agents), and Zegfrovy (EGFR+ NSCLC lung cancer). A pre-quotation teleconference is scheduled for November 17, 2026, with details in Part 2.4. The attached RFQ includes UF BPA and UF ADP appendices, instructions, and points of contact.